MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$2,736,000K
Net Income
$97,500K
Net Profit Margin
3.56%
EPS
$0.66
Unit: Thousand (K) dollars
Revenue Breakdown
US
Non Us
Royalty Attributed To OCREVUS
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
2,736,000
2,477,800
2,279,400
2,534,700
Cost of sales, excluding amortization and impairment of acquired intangible assets
776,900
661,000
495,500
674,400
Research and development
529,600
539,000
509,400
436,100
Acquired in-process research and development, upfront and milestone expense
164,000
34,000
222,400
2,100
Selling, general and administrative
709,700
607,300
682,500
594,800
Amortization and impairment of acquired intangible assets
168,200
136,500
136,600
135,700
Collaboration profit sharing/(loss reimbursement)
68,800
74,200
69,900
87,200
(gain) loss on fair value remeasurement of contingent consideration
-
-
-8,400*
-
Impairment of rou asset
-
-
49,700*
-
(gain) loss on fair value remeasurement of contingent consideration
2,500
20,500
-
5,600
Restructuring charges
165,400
7,900
6,600
7,400
Gain on sale of priority review voucher, net
-
-
0*
0
Other (income) expense, net
-18,500
-19,700
-154,400
-34,100
Total cost and expense
2,603,600
2,100,100
2,335,400
1,977,400
Income before income tax (benefit) expense
132,400
377,700
-56,000
557,300
Income tax (benefit) expense
34,900
58,200
-7,100
90,800
Net income
-
-
-48,900*
-
Net income attributable to noncontrolling interests, net of tax
-
-
0*
-
Net income attributable to biogen inc
97,500
319,500
-48,900
466,500
Basic EPS
0.66
2.17
-0.333
3.18
Diluted EPS
0.66
2.15
-0.33
3.17
Basic Average Shares
147,700,000
147,200,000
146,800,000
146,600,000
Diluted Average Shares
148,700,000
148,400,000
148,000,000
147,100,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
US
$1,114,500K
(18.43%↑ Y/Y)
Non Us
$801,900K
(-14.47%↓ Y/Y)
Royalty Attributed To
OCREVUS
$381,400K
(7.80%↑ Y/Y)
Biogen's share of pre-tax
profits in the u.s. for...
$125,700K
(16.71%↑ Y/Y)
Other revenues from
anti-cd20 therapeutic...
$6,400K
(10.34%↑ Y/Y)
Contract Manufacturing
And Other Revenue
$232,400K
(3.29%↑ Y/Y)
Royalty
$10,000K
(-48.98%↓ Y/Y)
Product
$1,916,400K
(2.01%↑ Y/Y)
Revenuesfromanticd20therapeuticprograms
$513,500K
(9.89%↑ Y/Y)
Product And Service
Other
$242,400K
(-0.90%↓ Y/Y)
LEQEMBICollaboration
$63,700K
(16.03%↑ Y/Y)
Total revenue
$2,736,000K
(3.42%↑ Y/Y)
Income before income
tax (benefit)...
$132,400K
(-82.20%↓ Y/Y)
Total cost and expense
$2,603,600K
(36.92%↑ Y/Y)
Net income
attributable to biogen inc
$97,500K
(-84.64%↓ Y/Y)
Income tax (benefit)
expense
$34,900K
(-68.04%↓ Y/Y)
Cost of sales,
excluding amortization...
$776,900K
(28.41%↑ Y/Y)
Selling, general and
administrative
$709,700K
(21.57%↑ Y/Y)
Research and development
$529,600K
(32.73%↑ Y/Y)
Amortization and impairment
of acquired...
$168,200K
(28.50%↑ Y/Y)
Restructuring charges
$165,400K
(23728.57%↑ Y/Y)
Acquired in-process
research and...
$164,000K
(251.93%↑ Y/Y)
Collaboration profit
sharing/(loss reimbursement)
$68,800K
(-8.27%↓ Y/Y)
Other (income)
expense, net
-$18,500K
(62.01%↑ Y/Y)
(gain) loss on fair
value remeasurement...
$2,500K
(-81.06%↓ Y/Y)
Buy us a coffee
Biogen-svg
BIOGEN INC. (BIIB)
Biogen-svg
BIOGEN INC. (BIIB)